CellaVision launches Bone Marrow Aspirate Application in EMEA

AI-powered digital workflow brings greater consistency, efficiency, and collaboration to bone marrow morphology

CellaVision today announced the launch of the CellaVision® Bone Marrow Aspirate (BMA) Application across the EMEA region, extending its digital cell morphology platform into bone marrow aspirate analysis — one of the most complex areas in laboratory diagnostics. 

The application is CE marked as a Class C device/product under the European Union In Vitro Diagnostic Regulation (EU IVDR), confirming compliance with stringent requirements for safety, performance, and quality. With the regulatory milestone in place, laboratories in EMEA can now implement a digital, AI-assisted workflow for bone marrow morphology. 

Digitalizing a complex diagnostic discipline 
Bone marrow aspirate examination remains central to diagnosing and monitoring blood cancers and other serious blood diseases. However, the process is typically manual, time-consuming, and highly dependent on specialist expertise. Inter-observer variability and increasing demands for faster turnaround times add further pressure on hematology and pathology laboratories. 

The CellaVision® BMA Application runs on the CellaVision® DC-1 analyzer using genuine 100× magnification. The software automatically locates suitable analysis areas, captures high-resolution images, and pre-classifies nucleated cells into 17 cell types based on morphology. 

Standardized and collaborative review 
Using the accompanying CellaVision® BMA Review Software, qualified users can review and verify differentials at the instrument or remotely within the laboratory network. The system supports multi-slide case handling, side-by-side comparisons with previous results or reference images, and full image traceability. Results can be exported to the laboratory information system (LIS) or generated as PDF reports. 

The solution can be configured as a stand-alone system or as part of a connected network. When multiple analyzers are installed, CellaVision® BMA Server Software provides centralized database management and LIS communication, enabling remote review and collaboration across sites. 

By digitalizing key steps in bone marrow morphology — including area selection, image capture, and pre-classification — the application aims to reduce manual workload, support standardized assessment, and facilitate collaboration between pathologists, hematologists, and laboratory scientists. 

“Bone marrow morphology places high demands on both expertise and time,” says Peter Wilson, VP Global Marketing at CellaVision. “With the EMEA launch of the CellaVision® Bone Marrow Aspirate Application, we are bringing AI-assisted digital workflows to this critical discipline, supporting laboratories in delivering more consistent and traceable results.” 

Commercial collaboration 
CellaVision collaborates with Sysmex Corporation as distribution partner for the CellaVision® BMA Application. Sysmex holds the highest global market share in the large hematology segment, providing broad market reach and established relationships with hospital and reference laboratories across the region. 
 
Built on a proven digital platform 
The CellaVision® DC-1 analyzer has been commercially available since 2019 and is widely used for digital peripheral blood morphology. With the addition of the BMA Application, laboratories can analyze both peripheral blood and bone marrow samples within one integrated digital platform.